Iron Mountain Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Iron Mountain Inc trades at $114.51 (market cap $34.46B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.65 (market cap $2.27B). The key difference: Iron Mountain Inc is far larger — about 15.2× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Iron Mountain Inc pays a 2.99% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IRM | SLS | |
|---|---|---|
Market Cap | $34.46B | $2.27B |
Volume | 1,379,608 | 4,179,659 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $15.46 |
52-Week Low | $78.86 | $1.39 |
Typical Hold Time | 80 Days | — |
Enterprise Value | $53.87B | $2.14B |
Dividend Yield | 2.99% | — |
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $112.97, down 2.38% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed from 10.91% to 2.09% over the same period. Recent news highlights expansion in data center capacity and digital partnerships, while institutional investors show mixed positioning with significant options activity.
The stock presents a growth story with data center expansion driving revenue, but faces headwinds from high debt levels (79.04% debt-to-asset ratio) and margin pressure. Analyst consensus remains bullish with a $142.75 price target representing 26% upside, though technical indicators suggest near-term caution. Key risks include interest rate sensitivity and execution challenges in digital transformation initiatives.
No Aura AI signal available yet.
Trailing returns across standard periods
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →